Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi
暂无分享,去创建一个
S. Sacchi | A. Santoro | L. Baldini | L. Marcheselli | F. Di Raimondo | P. Musto | A. Ferrari | F. Silvestris | G. Specchia | A. Carella | D. Vallisa | G. Buda | S. Pozzi | R. Marcheselli | A. Bari | A. Molinari | S. Ronconi | M. Cesaretti | L. Guardigni | Annalisa Chiapella
[1] M. Czuczman,et al. Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] C. Buske. Towards a chemotherapy-free approach in indolent lymphoma. , 2014, The Lancet. Oncology.
[3] Michael L. Wang,et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. , 2014, The Lancet. Oncology.
[4] J. Leonard,et al. CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma. , 2014 .
[5] J. Burke,et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. , 2014, Blood.
[6] J. Tuscano,et al. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non‐Hodgkin lymphoma , 2014, British journal of haematology.
[7] J. Vose,et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Michael L. Wang,et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo , 2009, American journal of hematology.
[9] M. Czuczman,et al. Immunomodulatory drugs stimulate natural killer‐cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti‐tumour activity of rituximab in vivo , 2007, British journal of haematology.
[10] F. Angrilli,et al. Introduction of rituximab in front‐line and salvage therapies has improved outcome of advanced‐stage follicular lymphoma patients , 2007, Cancer.
[11] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] R. Levy,et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] P. Thall,et al. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. , 1995, Statistics in medicine.